Trailing-twelve-month (TTM) revenue is $2.59 Billion with a year-over-year growth of +1.37%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $653,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $693,200,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Q1 FY2026Period ended 2026-03-31 | $592,100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $651,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $2,589,300,000 |
Current P/S: $9,940,853,115 market capitalization ÷ $2,589,300,000 TTM revenue = 3.84x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $651.00M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-14T12:20:21.375Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Clinical Diagnostics | $1.3B | $1.5B | $1.5B | $1.5B | $1.5B | $1.6B |
| Life Science | $1.2B | $1.4B | $1.3B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Americas | $137M | $157M | $155M | $167M | $169M | $165M |
| Asia Pacific | $547M | $688M | $639M | $563M |
$2.59B
$2.59 Billion
+1.37%
vs. $2.55B a year ago (TTM)
+0.29%
5 Year compound annual growth rate
1 Year
+1.37%
3 Year
(2.21%)
5 Year
+0.29%
10 Year
+2.47%
15 Year
+1.70%
20 Year
+3.85%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.58B | +$16.70M | +0.65% |
| 2024 | $2.57B | ($104.76M) | (3.92%) |
| 2023 | $2.67B | ($130.99M) | (4.67%) |
| 2022 | $2.80B | ($120.30M) | (4.12%) |
| 2021 | $2.92B | +$376.92M | +14.81% |
| 2020 |
TTM Growth
+1.37%
3-Year CAGR
(2.21%)
5-Year CAGR
(2.10%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-14T12:20:21.375Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $1.0B |
| $1.0B |
| $513M |
| Europe | $858M | $947M | $852M | $820M | $834M | $882M |
|---|
| UNITED STATES | $1.0B | $1.1B | $1.2B | $1.1B | $1.0B | $1.0B |
|---|
| $2.55B |
| +$233.97M |
| +10.12% |
| 2019 | $2.31B | +$21.55M | +0.94% |
| 2018 | $2.29B | +$129.96M | +6.02% |
| 2017 | $2.16B | +$91.98M | +4.45% |
| 2016 | $2.07B | +$48.73M | +2.41% |
